Century Therapeutics, Inc.

How big is Century Therapeutics, Inc.?

As of Jun 18, Century Therapeutics, Inc. has a market capitalization of 50.94 million and reported net sales of 114.89 million with a net profit of -21.95 million over the last four quarters. Shareholder's funds are 161.36 million, and total assets amount to 353.22 million.

As of Jun 18, Century Therapeutics, Inc. has a market capitalization of 50.94 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 114.89 million, while the sum of net profit for the same period is -21.95 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 161.36 million, and total assets amount to 353.22 million.

What does Century Therapeutics, Inc. do?

Century Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $109 million and a net profit of $77 million as of March 2025. It has a market cap of $50.94 million, with key metrics indicating it is currently loss-making and does not pay dividends.

Overview: <BR>Century Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 109 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 77 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 50.94 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.67 <BR>Return on Equity: -7.99% <BR>Price to Book: 0.21<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Century Therapeutics, Inc.?

Is Century Therapeutics, Inc. overvalued or undervalued?

As of May 16, 2022, Century Therapeutics, Inc. is considered risky and overvalued, with poor financial metrics and a year-to-date return of -49.8%, significantly underperforming the S&P 500's gain of 12.22%.

As of 16 May 2022, the valuation grade for Century Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company is considered overvalued based on its current metrics, particularly given its Price to Book Value of 0.22, an EV to EBIT of 3.58, and an EV to EBITDA of 6.45. Comparatively, peers such as TScan Therapeutics, Inc. have a more favorable EV to EBITDA of 0.5157, while Vaxart, Inc. shows a negative EV to EBITDA of -1.3649, highlighting Century's relative weakness in profitability and valuation.<BR><BR>The stock has significantly underperformed against the S&P 500, with a year-to-date return of -49.8% compared to the index's gain of 12.22%. This stark contrast reinforces the notion that Century Therapeutics is struggling to deliver value to its shareholders amidst a challenging market environment.

Is Century Therapeutics, Inc. technically bullish or bearish?

As of August 14, 2025, Century Therapeutics, Inc. shows a mildly bearish technical trend with mixed signals from various indicators, having significantly underperformed the S&P 500 with a year-to-date decline of 49.8%.

As of 14 August 2025, the technical trend for Century Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also supports this view. However, the daily moving averages are bearish, and the Bollinger Bands are mildly bearish on both weekly and monthly time frames. The KST and Dow Theory present a bearish and mildly bullish outlook respectively on the weekly chart, with no trend on the monthly chart. <BR><BR>In terms of performance, Century Therapeutics has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 49.8% versus the S&P's gain of 12.22%, and a one-year decline of 69.27% compared to the S&P's 17.14%. Overall, the current technical stance is mildly bearish, reflecting mixed signals across different indicators.